title: Graves' disease following immune reconstitution or immunomodulatory treatment: should we manage it any differently?
abstract: Graves' disease and other disorders of thyroid function may occur following treatment with novel anticancer agents or during periods of lymphocyte recovery after lymphopenia. There are three main settings for such lymphocyte reconstitution: recovery after a bone marrow or haematopoietic stem cell transplant, alemtuzumab treatment and the use of highly active antiretroviral therapy (HAART) for human immunodeficiency virus infection. The available evidence suggests that Graves' disease behaves as normal in most of these cases and should be treated conventionally, but it may follow a more favourable course in those receiving alemtuzumab or HAART. As spontaneous or drug-induced remission may be more likely in these two settings, first-line treatment should usually consist of an antithyroid drug.
authors: Department of Human Metabolism, Faculty of Medicine Dentistry and Health, The Medical School, University of Sheffield, Sheffield, UK.
authors: Anthony P
authors: AP
authors: Weetman
mesh_terms: D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D001854:Bone Marrow Cells / Q000166:cytology; D004704:Endocrinology / Q000379:methods; D006111:Graves Disease / Q000209:etiology* / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007107:Immune System; D008214:Lymphocytes / Q000166:cytology; D008231:Lymphopenia / Q000276:immunology; D009369:Neoplasms / Q000150:complications / Q000628:therapy*; D012074:Remission Induction
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000074323:Alemtuzumab